Cargando…
Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer
Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721573/ https://www.ncbi.nlm.nih.gov/pubmed/31408948 http://dx.doi.org/10.3390/cancers11081153 |
_version_ | 1783448374527131648 |
---|---|
author | Hayashi, Takuji Fujita, Kazutoshi Matsushita, Makoto Nonomura, Norio |
author_facet | Hayashi, Takuji Fujita, Kazutoshi Matsushita, Makoto Nonomura, Norio |
author_sort | Hayashi, Takuji |
collection | PubMed |
description | Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies. Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. Interventions by medications and diets to control systemic and/or local inflammation might be effective therapies for prostate cancer progression. Epidemiological investigations and basic research using human immune cells or mouse models have revealed that non-steroidal anti-inflammatory drugs, metformin, statins, soy isoflavones, and other diets are potential interventions for preventing progression of prostate cancer by suppressing inflammation. It is essential to evaluate appropriate indications and doses of each drug and diet. |
format | Online Article Text |
id | pubmed-6721573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67215732019-09-10 Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer Hayashi, Takuji Fujita, Kazutoshi Matsushita, Makoto Nonomura, Norio Cancers (Basel) Review Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies. Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. Interventions by medications and diets to control systemic and/or local inflammation might be effective therapies for prostate cancer progression. Epidemiological investigations and basic research using human immune cells or mouse models have revealed that non-steroidal anti-inflammatory drugs, metformin, statins, soy isoflavones, and other diets are potential interventions for preventing progression of prostate cancer by suppressing inflammation. It is essential to evaluate appropriate indications and doses of each drug and diet. MDPI 2019-08-12 /pmc/articles/PMC6721573/ /pubmed/31408948 http://dx.doi.org/10.3390/cancers11081153 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hayashi, Takuji Fujita, Kazutoshi Matsushita, Makoto Nonomura, Norio Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer |
title | Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer |
title_full | Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer |
title_fullStr | Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer |
title_full_unstemmed | Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer |
title_short | Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer |
title_sort | main inflammatory cells and potentials of anti-inflammatory agents in prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721573/ https://www.ncbi.nlm.nih.gov/pubmed/31408948 http://dx.doi.org/10.3390/cancers11081153 |
work_keys_str_mv | AT hayashitakuji maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer AT fujitakazutoshi maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer AT matsushitamakoto maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer AT nonomuranorio maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer |